Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cannabis extract therapeutics - Cannabis Science

Drug Profile

Research programme: cannabis extract therapeutics - Cannabis Science

Alternative Names: CBIS GAP-001; CBIS LC-001; CBIS OBLD-001; CBIS OCD-001; CBIS PC-001; CBIS PPC-001; CBIS PS-001; CBIS SD-001; CBIS SSA-001; CBIS-OS-001; CBIS-PTSD-001; CS NEURO 1; CS-S/BCC-1; CS-TATI-1; Phytocannabinoid-based pharmaceutical products - Cannabis Science

Latest Information Update: 28 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cannabis Science
  • Developer Cannabis Science; Italian Institute for Health and Science on Ageing
  • Class Analgesics; Anti-inflammatories; Antianaemics; Antineoplastics; Antiretrovirals; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Skin disorder therapies; Sleep disorder therapies
  • Mechanism of Action Cannabinoid receptor modulators; Human immunodeficiency virus tat gene product inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Adult respiratory distress syndrome; Anaemia; Anxiety disorders; Arthritis; Attention-deficit hyperactivity disorder; Autistic disorder; Cancer; Dyskinesias; Fibromyalgia; HIV infections; Kaposi's sarcoma; Lung cancer; Neurological disorders; Neuropathic pain; Obsessive-compulsive disorders; Pain; Pancreatic cancer; Post-traumatic stress disorders; Prostatitis; Respiratory tract disorders; Rheumatic disorders; Sickle cell anaemia; Skin cancer; Skin disorders; Sleep disorders; Wounds

Most Recent Events

  • 28 Sep 2023 No recent reports of development identified for preclinical development in Anaemia in USA
  • 28 Sep 2023 No recent reports of development identified for preclinical development in Anxiety-disorders in USA
  • 28 Sep 2023 No recent reports of development identified for preclinical development in Arthritis in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top